Prospect and Current Situation of Immune Checkpoint Inhibitors 
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients

Prospect and Current Situation of Immune Checkpoint Inhibitors 
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients

With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and...

Full description

Bibliographic Details
Main Authors: Haiyang WANG, Xiaoqing YU, Yun FAN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2017-06-01
Series:Chinese Journal of Lung Cancer
Subjects:
PD-1/PD-L1 inhibitors
Lung neoplasms
First-line treatment
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.10

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.10

Similar Items